3-Ethyl-5-methyl (±) - 2 - [(2 - aminoethoxy)methyl] - 4 - (2 - chlorophenyl) - 1,4 - dihydro - 6 - methyl - 3,5 - pyridinedicarboxylate, monobenzenesulphonate monohydrate

Absorption
Tmax is 6 to 12 h.

Distribution
Bioavailability is 64% to 90%. About 93% is protein bound.

Metabolism
About 90% is converted to inactive metabolites in the liver.

Elimination
10% of the parent compound and 60% of the metabolites are excreted in the urine. Elimination is biphasic. T½ is about 30 to 50 h.

Duration
24 h.

Special Populations
Hepatic Function Impairment
Clearance is decreased and AUC may increase about 40% to 60%. May require lower initial dose.

Elderly
Clearance is decreased and AUC may increase about 40% to 60%. May require lower initial dose.

Moderate to severe heart failure
Clearance is decreased and AUC may increase about 40% to 60%. May require lower initial dose.

May cause increased adverse cardiac reactions as a result of myocardial depression.

Severe hypotension or increased fluid volume requirements have occurred with similar drug.